z-logo
open-access-imgOpen Access
The clinical significance of serum chitinase 3‐like 1 in hepatitis B–related chronic liver diseases
Author(s) -
Jiang Zhenluo,
Wang Shuwei,
Jin Jiancheng,
Ying Sheng,
Chen Zhigang,
Zhu Dedong,
Xiao Bingxiu,
Hu Yaoren,
Qian Yunsong,
Cai Ting,
Fu Liyun
Publication year - 2020
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.23200
Subject(s) - hepatocellular carcinoma , cirrhosis , medicine , gastroenterology , receiver operating characteristic , hepatitis b virus , chronic hepatitis , stage (stratigraphy) , fibrosis , clinical significance , hepatic fibrosis , hepatitis b , virus , immunology , biology , paleontology
Aim In the present study, we purposed to determine serum chitinase 3‐like 1 (CHI3L1) expression characteristics in chronic liver diseases monoinfected with hepatitis B virus and analyze its diagnostic value in liver fibrosis. Methods A total of 467 chronic hepatitis B (CHB) patients, 312 liver cirrhosis (LC) patients, and 104 hepatocellular carcinoma (HCC) patients at our institution were enrolled, and clinical indicators were analyzed. Results Our data have shown that the expression level of serum CHI3L1 was steadily increased from CHB to LC to HCC ( P  < .001). Serum CHI3L1 expression levels were positively associated with liver stiffness measurement (LSM), fibrosis‐4 (FIB‐4) index, aspartate aminotransferase‐to‐platelet ratio index (APRI), and HCC stage. The receiver operating characteristic (ROC) curve proved that serum CHI3L1 was superior to other noninvasive methods (LSM, FIB‐4, and APRI) with an area under the ROC curve (AUC) of 0.97 in diagnosing significant fibrosis. Conclusions Serum CHI3L1 harbors significant clinical value in chronic liver diseases infected with hepatitis B virus, especially in the diagnosis of fibrosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here